EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model

Juri Ichikawa, Hiroshi Okuda iD, Kuniyuki Kawano, Shingo Kato iD, Shinya Sato iD, Ryo Kuroishikawa, Daisuke Kurotaki, Wataru Kawase, Haruka Yoshida, Yukihiko Hiroshima, Itaru Endo, Shin Maeda iD und 1 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Juri Ichikawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Pancreatic Intraductal Neoplasms, Immune Checkpoint Inhibitors, CD40 Antigens, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, The research fund from Eisai Co., Ltd., Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all cancer types. Immune checkpoint inhibitors (ICIs) are currently not indicated for patients with PDAC except for those with high microsatellite instability. In this study, we developed an immunocompetent orthotopic transplant mouse model with Kras and Trp53 mutations, characterized by high fibrosis and an immunosuppressive tumor microenvironment, closely mimicking human PDAC lesions. This model provides a robust platform for investigating strategies for improving ICI efficacy. We observed that ICI monotherapy yielded minimal efficacy, whereas anti‐CD40 agonist antibody (aCD40) monotherapy prolonged survival despite its low impact on primary tumor volume. Moreover, ICIs + aCD40 combination therapy not only extended survival but also significantly reduced tumor burden. These effects were accompanied by enhanced dendritic cell migration to the lymph nodes and T cell priming and activation. Moreover, the expression of immunosuppressive markers in tumor‐associated macrophages was decreased. Indeed, gene expression analyses of infiltrating immune cells have revealed a shift in the tumor microenvironment from an immune‐tolerant state to an immune‐activated state. Our findings suggest that combination therapy with ICIs and aCD40 is a promising treatment strategy for patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic Intraductal NeoplasmsImmune Checkpoint InhibitorsCD40 AntigensAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAnimalsMiceDisease Models, AnimalPancreatic DuctsTumor BurdenDendritic CellsTumor-Associated MacrophagesTumor Microenvironment

Stichwörter der Autor:innen

CD40 antigenanimaldisease modelsimmune checkpoint inhibitorspancreatic cancertumor microenvironment

Substanzen

Immune Checkpoint InhibitorsCD40 AntigensAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Clinical Cancer Genomics, Yokohama City University Hospital, Kanagawa, Japan.
  • Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
  • Laboratory of Chromatin Organization in Immune Cell Development, International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Advanced Cancer Therapeutics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.

ORCID-Profile: Hiroshi Okuda, Shingo Kato, Shinya Sato, Shin Maeda, Tomohiko Tamura

Förderung

  • Japan Agency for Medical Research and Development
  • The research fund from Eisai Co., Ltd.
  • Japan Society for the Promotion of Science
  • Support for Pioneering Research Initiated by the Next Generation
  • Strategic Research Promotion at Yokohama City University
  • Yokohama City University research grant "KAMOME Project"

Zitieren

APA

Ichikawa, J., Okuda, H., Kawano, K., Kato, S., Sato, S., Kuroishikawa, R., Kurotaki, D., Kawase, W., Yoshida, H., Hiroshima, Y., Endo, I., Maeda, S., & Tamura, T. (2026). A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Cancer Science. https://doi.org/10.1111/cas.70246

Vancouver

Ichikawa J, Okuda H, Kawano K, Kato S, Sato S, Kuroishikawa R, et al. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Cancer Science. 2026. doi:10.1111/cas.70246

BibTeX
@article{Ichikawa2026,
  author = {Ichikawa, Juri and Okuda, Hiroshi and Kawano, Kuniyuki and Kato, Shingo and Sato, Shinya and Kuroishikawa, Ryo and Kurotaki, Daisuke and Kawase, Wataru and Yoshida, Haruka and Hiroshima, Yukihiko and Endo, Itaru and Maeda, Shin and Tamura, Tomohiko},
  title = {A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70246}
}
Kostenlos starten →